Emergent BioSolutions Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/27/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Emergent BioSolutions (EBS) Misses Q1 EPS by 22c, Offers Guidance
May 2, 2019 4:54 PM EDTEmergent BioSolutions (NYSE: EBS) reported Q1 EPS of ($0.13), $0.22 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $190.6 million versus the consensus estimate of $201.16 million.
GUIDANCE:
Emergent BioSolutions sees Q2 2019 revenue of $200-220 million, versus the consensus of $254.14... More
